Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors.

Antineoplastic Agents / pharmacology Enzyme Inhibitors / pharmacology Humans Neoplasms / drug therapy Telomerase / antagonists & inhibitors Telomere

Journal

Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391

Informations de publication

Date de publication:
07 2019
Historique:
received: 21 03 2019
revised: 02 05 2019
accepted: 21 05 2019
pubmed: 29 5 2019
medline: 14 5 2020
entrez: 29 5 2019
Statut: ppublish

Résumé

Telomerase is a ribonucleic reverse transcriptase enzyme that uses an integral RNA component as a template to add tandem telomeric DNA repeats, TTAGGG, at the 3' end of the chromosomes. 85-90% of human tumors and their derived cell lines predominantly express high levels of telomerase, therefore contributing to cancer cell development. However, in normal cells, telomerase activity is almost always absent except in germ cells and stem cells. This differential expression has been exploited to develop highly specific and potent cancer therapeutics. In this review, we outline recent advances in the development of telomerase inhibitors as anticancer agents.

Identifiants

DOI: 10.1016/j.drudis.2019.05.015 PMID: 31136800
pubmed: 31136800
pii: S1359-6446(18)30545-2
doi: 10.1016/j.drudis.2019.05.015
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Enzyme Inhibitors 0
Telomerase EC 2.7.7.49

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1370-1388

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

A Prasanth Saraswati (AP)

University of Siena, Department of Biotechnology, Chemistry and Pharmacy, DoE Department of Excellence 2018-2022, via Aldo Moro 2, I-53100 Siena, Italy.

Nicola Relitti (N)

University of Siena, Department of Biotechnology, Chemistry and Pharmacy, DoE Department of Excellence 2018-2022, via Aldo Moro 2, I-53100 Siena, Italy.

Margherita Brindisi (M)

University of Napoli Federico II, Department of Pharmacy, DoE Department of Excellence 2018-2022, via D. Montesano 49, I-80131 Napoli, Italy.

Sandra Gemma (S)

University of Siena, Department of Biotechnology, Chemistry and Pharmacy, DoE Department of Excellence 2018-2022, via Aldo Moro 2, I-53100 Siena, Italy.

Daniela Zisterer (D)

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160, Pearse Street, Dublin 2, Ireland.

Stefania Butini (S)

University of Siena, Department of Biotechnology, Chemistry and Pharmacy, DoE Department of Excellence 2018-2022, via Aldo Moro 2, I-53100 Siena, Italy. Electronic address: butini3@unisi.it.

Giuseppe Campiani (G)

University of Siena, Department of Biotechnology, Chemistry and Pharmacy, DoE Department of Excellence 2018-2022, via Aldo Moro 2, I-53100 Siena, Italy. Electronic address: campiani@unisi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Raising the bar in anticancer therapy: recent...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Raising the bar in anticancer therapy: recent...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Raising the bar in anticancer therapy: recent...
questionsmedicales.fr › Tumeurs › Raising the bar in anticancer therapy: recent...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines de liaison à l'ARN › Ribonucléoprotéines › Telomerase › Raising the bar in anticancer therapy: recent...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Structures de chromosome › Télomère › Raising the bar in anticancer therapy: recent...